2 Canadian Marijuana Stocks to Avoid in 2020

Here’s why contrarian investors need to avoid Aurora Cannabis (TSX:ACB) and Hexo (TSX:HEXO) shares right now!

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Marijuana stocks have been on a downward spiral for close to 18 months now. The pot industry has been impacted by structural issues that include oversupply, a thriving black market, tepid demand, mounting losses, regulatory issues, and many more.

The bull run that ended when marijuana was legalized for recreational use in Canada seems like a distant dream right now. While the lower valuation multiples of pot stocks might be attractive to contrarian investors, there are a few companies that are weak fundamentally and remain risky buys, despite the massive declines.

We’ll look at two such cannabis stocks investors need to avoid, at least in 2020.

Aurora Cannabis stock will be range bound

Aurora Cannabis (TSX:ACB)(NYSE:ACB) is one of the largest cannabis companies in the world. It’s trading at a market cap of $1.03 billion and has lost 95% since touching a record high in October 2018.

Aurora Cannabis was widely expected to lead cannabis production and exports given its huge production facilities and market presence. However, the company has had to stop production in two of its largest projects to reduce cash burn and improve profit margins.

In the last few years, Aurora has raised significant equity and debt capital to keep operations running, which has diluted shareholder wealth and pressurized financials. Further, over 50% of the company’s assets are classified as goodwill, indicating the company paid a hefty premium for its acquisitions over the years.

Aurora expects fiscal Q4 net sales between $70 million and $72 million with net cannabis sales between $66 million and $68 million. This was below the company’s net cannabis sales of $69.6 million in the third quarter. ACB said it will record $1.8 billion in goodwill impairment charges in Q4 and $140 million in impairment charges related to the carrying value of inventory.

Aurora Cannabis had previously said it expects to report an adjusted EBITDA profitability in the first quarter of fiscal 2021, ending in September. It has now delayed its EBITDA profitability expectations to Q2 of 2021.

Hexo stock is down 85% from 52-week highs

Shares of Hexo (TSX:HEXO)(NYSE:HEXO) are trading at $0.89, which is 85% below its 52-week high and 92% below its record high. Similar to Aurora Cannabis, Hexo is also grappling with widening losses and massive cash burn. The company recently raised $34.5 million after floating an at-the-market stock issue.

In order to cut costs, Hexo sold off its Niagara grow farm that it acquired via the Newstrike acquisition last year. Hexo also had to lay off its workforce to reduce costs and improve its bottom line amid the COVID-19 pandemic.

Another reason for concern is Hexo’s share price has been trading below US$1 for several months, which might compel the New York Stock Exchange to delist the stock. Hexo will most likely have to engineer a reverse stock split to keep trading on the NYSE.

The Foolish takeaway

We can see why the two companies are not out of the woods as yet. Cannabis is highly regulated in Canada and is illegal at the Federal level in the United States. This makes it difficult to raise debt capital at traditional rates.

The high cost of capital combined with negative profit margins and slowing revenue growth for Aurora and Hexo make them high-risk bets right now.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends HEXO. and HEXO. Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »